EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The contemporary management of haemolytic disease of the fetus and newborn

Mark D Kilby iD, James B Bussel, Kenneth J Moise

Vox Sanguinis · 2025-07 · 120 (7) · 644-652

DOI: 10.1111/vox.70027 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vox Sanguinis, online erschienen am 22.04.2025. Verfasst von Mark D Kilby und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Medical Science, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: Erythroblastosis, Fetal, Immunoglobulins, Intravenous, Blood Transfusion, Intrauterine. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 92 Literaturangaben. Gefördert von: Johnson and Johnson, Inc., Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Haemolytic disease of the fetus and newborn (HDFN) remains an important cause of perinatal mortality and morbidity. The pathogenesis underlying this condition is maternal red cell alloimmunization, with immunoglobulin G (IgG) antibodies produced in response to ‘non‐self’, inherited paternal antigens expressed upon fetal erythrocytes. The IgG antibodies cross the placenta into the fetal circulation causing red cell destruction and fetal anaemia. Intrauterine transfusion (IUT) remains the cornerstone therapy with fetal survival rates up to 97%, but it is an invasive, technically challenging surgical procedure performed at specialized medical centres. The procedure‐related risk of IUTs is increased at gestational age before 24 weeks. This has stimulated interest in maternal medical therapies that attenuate the risk of severe fetal anaemia, increase the gestational age of first IUTs, and reduce perinatal mortality and morbidity. This review summarizes current evidence for such treatments: intravenous immunoglobulin therapy and neonatal fragment crystallizable (Fc) receptor blockade for managing severe HDFN.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erythroblastosis, FetalImmunoglobulins, IntravenousBlood Transfusion, IntrauterineHumansInfant, NewbornFemalePregnancyReceptors, Fc

Stichwörter der Autor:innen

alloimmunizationanaemiaanti‐Dfetal therapyfetus

Substanzen

Immunoglobulins, IntravenousReceptors, Fc

Autor:innen und Institutionen

  • College of Medical Science, University of Birmingham, Birmingham, UK.
  • Fetal Medicine Centre, Birmingham Women's and Children's Foundation Trust, Birmingham, UK.
  • Weill Cornell School of Medicine, New York, New York, USA.
  • Department of Women's Health, Dell Medical School-University of Texas at Austin, Austin, Texas, USA.
  • Comprehensive Fetal Care Center, Dell Children's Medical Center, Austin, Texas, USA.

ORCID-Profile: Mark D Kilby

Förderung

  • Johnson and Johnson, Inc.
  • Johnson and Johnson

Zitieren

APA

Kilby, M. D., Bussel, J. B., & Moise, K. J. (2025). The contemporary management of haemolytic disease of the fetus and newborn. Vox Sanguinis, 120(7), 644-652. https://doi.org/10.1111/vox.70027

Vancouver

Kilby MD, Bussel JB, Moise KJ. The contemporary management of haemolytic disease of the fetus and newborn. Vox Sanguinis. 2025;120(7):644-652. doi:10.1111/vox.70027

BibTeX
@article{Kilby2025,
  author = {Kilby, Mark D and Bussel, James B and Moise, Kenneth J},
  title = {The contemporary management of haemolytic disease of the fetus and newborn},
  journal = {Vox Sanguinis},
  year = {2025},
  volume = {120},
  number = {7},
  pages = {644--652},
  doi = {10.1111/vox.70027}
}
Kostenlos starten →